How It Works
EquiFlow is a cutting-edge biologic therapy designed to support your horse’s natural recovery process. Administered via a nebulizer—without the need for needles or drugs—this non-invasive remedy is given on rest days, not race days, to restore respiratory health. By delivering biologic molecules directly to the lungs, EquiFlow helps reduce inflammation, clear mucus, and support overall lung function. It’s a simple, science-backed approach to enhancing performance and well-being through restorative care.
One commonly accepted definition of EIPH describes it as a highly prevalent condition characterized by the presence of blood in the respiratory tract. It is caused by the rupture of the capillaries at the site of the blood gas barrier or alveoli.
Responsible for facilitating the efficient exchange of gases while breathing, the alveoli are ultrathin making them predisposed to rupture because of their ultra thinness. During extreme exertion and strenuous exercise, and a significant spike in blood pressure. The most extreme expression of EIPH is epistaxis.
What is EIPH?
Pre-Clinical & Safety Studies
Extensive experimentation was carried out in the laboratory on nebulizing the EquiFlow protein solution. The results demonstrated the positive transferability via nebulization and encouraged us to try it in horses.
Testing has shown that that the product poses no safety risks to horses when administered as directed.
Clinical Field Trials
-
Study conducted using 18 healthy, competitive thoroughbred race horses.
-
Focus: Evaluting the effects of ReCellerate's EquiFlow Therapy.
-
Administered via Flexineb Nebulizer.
-
18/18 horses successfully completed the study.
-
83% were confirmed Grade 3 & Grade 4 EIPH bleeders.
-
93% had a significant reduction in bleeding after racing.
-
73% showed no bleeding at all.
-
-
The nebulized product did not elicit any adverse reactions in the horses.
-
No signs of stress or discomfort were seen after therapy.
-
The study indicates that EquiFlow positively impacts performance and recovery in competitive horses supporting its potential benefits for equine athletes.
Overview:
Results:
Conclusion:
Why EquiFlow?
A Non-Invasive Approach to Equine Recovery
ReCellerate’s EquiFlow Presents a Healthy Biologic Option to Support the Reduction of Bleeding and Aid in the Natural Repair of the Damage Caused by Chronic EIPH
Lasix (furosemide) is commonly used to manage EIPH symptoms but is not a treatment. EIPH affects at least 65% of performance horses, with nearly all horses experiencing it at some point in their careers. It causes long-term lung damage, decreases performance, shortens careers, and leads to financial losses for owners. EquiFlow, a biologic solution, is not a performance enhancer.
